CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.